Skip to main content
NIH funding notice RFA-CA-18-004

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 - Clinical Trial Not Allowed)

Closed on September 28, 2018.

Posted
November 20, 2017
Close date
September 28, 2018
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $400,309 in first-year total cost, median $200,155.

Most frequent study sections

  1. Special Emphasis Panel[ZCA1 TCRB-J (J2)]1
  2. Special Emphasis Panel[ZCA1 TCRB-Q (M1)]1

Most frequent institutions

  1. NEW YORK STEM CELL FOUNDATION1
  2. WASHINGTON UNIVERSITY1
Competing awards under RFA-CA-18-004 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2019METAL-ORGANIC FRAMEWORK AS PROTECTIVE COATING FOR CANCER BIOSPECIMEN PRESERVATION1R21CA236652-01MORRISSEY, JEREMIAH JSINGAMANENI, SRIKANTHWASHINGTON UNIVERSITY, MO$204,559ZCA1
2019Establishing efficient technologies for ovarian cancer organoid derivation from fresh tumor resections1R21CA240219-01ANDRES-MARTIN, LAURANEW YORK STEM CELL FOUNDATION, NY$195,750ZCA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-11-0.1.2. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.